EC Number   |
Application |
Reference |
|---|
    5.3.99.4 | medicine |
after culture of embryos in presence of the selective cyclooxygenase-1 inhibitor SC560, the selective cyclooxygenase-2 inhibitor NS398, or the selective prostacyclin synthase inhibitor U51605 in a 48-h culture, the implantation rate decreases with exposure to either the cyclooxygenase-2 inhibitor of the prostaglandin-I synthase inhibitor, which is increased further after supplementation with prostaglandin I2. The level of prostaglandin I2 is also higher at the 8-16 cell stage, compaction and blastocyst stage than prostaglandin E2 |
694938 |
| 5.3.99.4 | medicine |
by impairing prostacyclin synthase function, and thus PGI2 release, C-reactive protein, CRP, could promote endothelial dysfunction and participate in the development of coronary artery disease |
705205 |
| 5.3.99.4 | medicine |
co-adjuvant therapy with enzyme enhancers, such as retinoids, has therapeutic value for head and neck squamous cell carcinoma treatment |
748449 |
| 5.3.99.4 | medicine |
exposure of isolated coronary arteries to high glucose switches angiotensin II-stimulated prostacyclin-dependent relaxation into a persitent vascoconstriction. High glucose, but not mannitol, significantly increases superoxide and nitration of tyrosine in prostacyclin synthase. Concurrent administration of polyethylene-coated superoxide dismutase, L-nitroarginine methyl ester, or sepiapterin abolishes enzyme nitration, as well as its association with endothelial nitric oxide synthase |
679435 |
| 5.3.99.4 | medicine |
formation of monoclonal antibodies against prostacyclin synthase |
37465, 37469 |
| 5.3.99.4 | medicine |
it is hypothesized that the combination of prostacyclin synthase overexpression and epidermal growth factor receptor tyrosine kinase inhibitor, EGFR TKI, would lead to augmented chemoprevention for lung cancer |
705476 |
| 5.3.99.4 | medicine |
manipulation of prostaglandin production distal to cyclooxygenase significantly reduces lung carcinogenesis in a tobacco smoke exposure model |
661425 |
| 5.3.99.4 | medicine |
overexpression of PGIS is highly effective in controlling vascular diseases and ischemia-reperfusion tissue injury, gene transfer of bicistronic COX-1/PGIS has the potential for treatment of diverse clinical disorders including vascular diseases, pulmonary hypertension, and ischemia-reperfusion cerebral and cardiac injury |
660924 |
| 5.3.99.4 | medicine |
prostacyclin synthase may be chemopreventive in cancer |
702474 |
| 5.3.99.4 | medicine |
prostacyclin synthase overexpression apparently protects insulin-producing cells against cytokine toxicity via suppression of endoplasmic reticulum and mitochondrial stress-mediated cell death pathways |
704650 |
